Overview
Denmark-based cell counting instrument maker's H1 revenue fell 1% yr/yr due to US slowdown
Sales of XcytoMatic instruments grew 60% organically despite US market challenges
EBITDA margin increased to 55% from 54% in the year-earlier period
Outlook
Chemometec maintains full-year revenue guidance at DKK 565-580 mln
Company sees strong growth potential in US cell and gene therapy market
Result Drivers
US MARKET SLOWDOWN - Revenue was affected by a sharp slowdown in US demand due to a historically long government shutdown
XCYTOMATIC GROWTH - Sales of XcytoMatic instruments grew organically by 60% despite US market challenges
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
DKK 249 mln
H1 EBITDA
DKK 136.20 mln
H1 EBITDA Margin
55.00%
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Chemometec A/S is DKK882.50, about 52.3% above its February 4 closing price of DKK579.50
The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 56 three months ago
Press Release: ID:nGNEb9GVpF
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
